Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317825 | 0.83 | AURKA (0.65) | AURKAMAPK8CHEK1PAK4CSNK2A2 | |
| SCHEMBL23510224 | 0.81 | ABL1 (0.62) | AURKAMAPK8MAPK10ABL1BCR | |
| Hydrochloric Acid SCHEMBL28133159 | 0.80 | ABL1 (0.61) | AURKAMAPK8MAPK10ABL1BCR | |
| Pyridine SCHEMBL1454611 | 0.79 | AURKA (0.61) | AURKAMAPK8CHEK1PAK4CSNK2A2 | |
| SCHEMBL4903032 | 0.79 | MAPK8 (0.74) | AURKAMAPK8CDK2CAMKK2PIK3CG | |
| SCHEMBL10960560 | 0.79 | KDM4E (0.48) | MAPK8MAPK1MAPK10SYKABL1 | |
| SCHEMBL4901365 | 0.78 | CAMKK2 (0.67) | MAPK8CAMKK2PIK3CGMAPK10SYK | |
| SCHEMBL4903688 | 0.77 | MAPK8 (0.63) | AURKAMAPK8CAMKK2PIK3CGMAPK10 | |
| SCHEMBL7465982 | 0.75 | FLT3 (0.50) | MAPK1SYKABL1BCRPRKCA | |
| SCHEMBL4520734 | 0.74 | CDK2 (0.68) | AURKAMAPK8CSNK2A2CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175301-A1 | POLYMER CONJUGATE OF MONTESANIB WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175302-A1 | POLYMER CONJUGATES TARGETING C-SRC WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-2166860-B1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | LI PENG (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9062023-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| US-20100111876-A1 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE | GUERBET (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2166860-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7687512-B2 | 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; for neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| WO-2008153974-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20070129389-A1 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders | NOVARTIS AG (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2005039586-A1 | USE OF PYRIDINYL-PYRIMIDINYLAMINO-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF AMYLOID RELATED DISORDERS | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, BACE1, PYGB | AURKA 83/4885MAPK8 498/4885CHEK1 97/4885 |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | AURKA 243/4885MAPK8 424/4885CHEK1 195/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | AURKA 165/4885MAPK8 372/4885CHEK1 157/4885 |
| US-20100184778-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, PYGB, BACE1 | AURKA 78/4885MAPK8 500/4885CHEK1 90/4885 |
| US-20100111876-A1 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | AURKA 2039/4885MAPK8 4661/4885CHEK1 4726/4885 |
| US-20070129389-A1 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders | TIE1, ABL2, FYN | AURKA 847/4885MAPK8 220/4885CHEK1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.